Phaseline

Targets › TMPRSS6

TMPRSS6 (Transmembrane protease serine 6): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Sep 2028.

Membrane-bound serine protease. Through the cleavage of cell surface hemojuvelin (HJV), a regulator of the expression of the iron absorption-regulating hormone hepicidin/HAMP, plays a role in iron homeostasis. (UniProt, Q8IU80)

Open in Phaseline: the race on TMPRSS6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ono PharmaceuticalSapablursen (ONO-0530)
Transmembrane protease serine 6 mRNA antisense inhibitor
TMPRSS6Phase 3Polycythemia VeraSep 2028
Silence TherapeuticsSLN124
siRNA targeting TMPRSS6 mRNA
TMPRSS6Phase 1Polycythemia VeraMar 2030

Conditions

Polycythemia Vera (2)

Modalities

other (1), small molecule (1)

Companies

Ono Pharmaceutical (1) Silence Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.